Table 1.
Descriptives of the sample
| Age (in years) mean ± SD | 65.95 ± 11.51 |
| Gender n (in %) | |
| Male | 225 (36.1%) |
| Female | 398 (63.9%) |
| Current condition n (in %) | |
| Alive | 580 (93.1%) |
| Deceased | 43 (6.9%) |
| Group tumor n (in %) | |
| Breast cancer | 211 (33.9%) |
| Melanoma/skin cancer | 111 (17.8%) |
| Gastrointestinal | 94 (15.1%) |
| Genitourinary | 69 (11.1%) |
| Gynecological | 55 (8.8%) |
| Lung | 43 (6.9%) |
| Othera | 40 (6.4%) |
| Stage n (in %) | |
| NED (no evidence of disease) | 316 (50.7%) |
| Metastatic | 307 (49.3%) |
| Ongoing therapy during vax period n (in %) | |
| Yes | 462 (74.2%) |
| No | 161 (25.8%) |
| Type of treatment n (in %) | |
| Chemotherapy | 164 (35.5%) |
| Immunotherapy | 82 (17.7%) |
| Hormone therapy | 82 (17.7%) |
| Target therapy | 76 (16.5%) |
| Chemotherapy - Target therapy | 39 (8.4%) |
| Target - Hormone therapy | 11 (2.4%) |
| Other treatmentb | 8 (1.8%) |
| Group treatment n (in %) | |
| Chemotherapy | 204 (32.7%) |
| Other | 258 (41.4%) |
| Follow up | 161 (25.9%) |
a
Other primary cancer diagnoses within our cohort: neuroendocrine (n = 1), head and neck (n = 13), central nervous system (n = 17), gastrointestinal stromal (n = 5), and peritoneal (n = 2) tumors, sarcoma (n = 2).
b
Other treatment within our cohort: bifosfonate (n = 6), chemio-immune therapy (n = 1), immune-target therapy (n = 1).